Outcome of hairy cell leukemia patients treated with cladribine - a 10-year single-center experience in Pakistan
Hematol., Transfus. Cell Ther. (Impr.)
;
41(2): 134-138, Apr.-June 2019. tab, graf
Artigo
em Inglês
| LILACS
| ID: biblio-1012179
ABSTRACT
ABSTRACT Introduction and objective:
Hairy cell leukemia is an uncommon, indolent B-cell lymphoproliferative disorder. Therapy with cladribine (2-chlorodeoxyadenosine) is able to induce complete remission (CR) in the majority of patients after a single course of treatment. We report the outcomes of patients treated at Aga Khan University Hospital, Karachi, Pakistan.Methods:
This was a retrospective review. Medical records of patients were used to collect data.Results:
A total of 21 patients with hairy cell leukemia were treated with cladribine. All patients achieved an initial CR. Four patients (19%) required hospitalization and therapy for neutropenic fever. Six patients (29%) relapsed at a median of 48 months. All 6 patients were treated for relapse, out of which 4 achieved CR, 1 had partial response and 1 had refractory disease. The overall survival rate was 90.5%, with a median follow-up of 35 months.Conclusion:
A single course of cladribine is able to induce CR in a vast majority of patients. Unfortunately, relapse is not uncommon. Patients who relapse can be successfully retreated with cladribine. Cladribine has impressive efficacy and a favorable acute and long-term toxicity profile when administered to patients with HCL.
Texto completo:
DisponíveL
Índice:
LILACS (Américas)
Assunto principal:
Leucemia de Células Pilosas
/
Cladribina
Limite:
Adulto
/
Idoso
/
Humanos
/
Masculino
Idioma:
Inglês
Revista:
Hematol., Transfus. Cell Ther. (Impr.)
Assunto da revista:
Hematologia
/
TransfusÆo de Sangue
Ano de publicação:
2019
Tipo de documento:
Artigo
País de afiliação:
Paquistão
/
Estados Unidos
Instituição/País de afiliação:
Aga Khan University/PK
/
Temple University Hospital/US
Similares
MEDLINE
...
LILACS
LIS